GMYTF yields 1.91% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 8
Combined, GMYTF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GMYTF + PFE for your $10,000?
GMO Payment Gateway, Inc., together with its subsidiaries, provides financial services and integrated payment related services. It operates through three segments: Payment Enhancement Business, Payment Processing Business, and Money Service Business. The company offers PG multi-payment service, a payment platform that provides credit card payment, convenience store payment, account transfer, and multi-currency credit card payment. It also provides GMO payment after delivery; Ginko Pay Base System, a smartphone app that enables payments to be made by an immediate debit from the bank account; and GMO-PG processing platform, which helps financial institutions or financial service providers start payment-related services by enabling payment infrastructure building, as well as security services. In addition, the company offers global payment services; and early payment, GMO-PG remittance, guarantees, and transaction lending services. Further, it offers online advertising services consisting of administrative services for listing ads that use Yahoo! Promotional Ads and Google AdWords; and administrative services for Facebook Ads, Google Analytics, etc. It serves online merchants and public organizations, such as NHK, National Tax Agency, and Tokyo Metropolitan Government; and banks and other financial institutions. GMO Payment Gateway, Inc. was founded in 1995 and is headquartered in Tokyo, Japan.
Full GMYTF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.